Home    Back

Risperdal    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
20322q11.2 deletion syndrome1

203. 22q11.2 deletion syndrome    [ 3 clinical trials,   3 drugs,   (DrugBank: 0),   0 drug target gene,   0 drug target pathway]
Searched query = "22q11.2 deletion syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04639960
(ClinicalTrials.gov)		September 29, 20173/11/2020Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion SyndromeEffects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome22q11.2 Deletion SyndromeDrug: Risperdal;Drug: PlaceboUniversity of Geneva, SwitzerlandNULLRecruiting11 Years25 YearsAll30N/ASwitzerland